Ilic Aleksandar, Tort Maria J, Cane Alejandro, Farkouh Raymond A, Rozenbaum Mark H
Pfizer Inc., Tadworth KT20 7NY, UK.
Pfizer Inc., Collegeville, PA 19426, USA.
Vaccines (Basel). 2024 Nov 14;12(11):1279. doi: 10.3390/vaccines12111279.
(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses are administered during the first year of life at 2, 4, and 6 months, while a booster dose is given at 12 to 15 months. This study evaluated the health and economic effects of the PCV20 infant series within the first year of life compared to PCV15. (2) Methods: Using a decision-analytic model, we calculated the health and economic effects of introducing PCV15 or PCV20 for five subsequent birth cohorts. Epidemiological data were drawn from peer-reviewed studies and estimates for vaccine effectiveness were extrapolated from established PCV13 effectiveness and PCV7 efficacy studies. Direct medical costs related to the disease treatment were extracted from the literature and inflated to 2024 dollars. (3) Results: Over the course of five years, the implementation of PCV20 vaccination for newborns in the United States, compared to PCV15, is projected to prevent an additional 220 cases of invasive pneumococcal disease, 6542 cases of community-acquired pneumonia, and 112,095 cases of otitis media within the first year of life across five subsequent birth cohorts. This strategy could prevent 66 infant deaths linked to these illnesses and confer extra health gains, amounting to 5058 years of life and 5037 quality-adjusted life years. These prevented cases are estimated to save approximately USD 147 million over 5 years. (4) Conclusions: This study demonstrated that vaccinating with PCV20 during the first 12 months of life compared to PCV15 in the US would yield a substantially greater health and economic return due to the five additional serotypes covered by PCV20.
（1）背景/目的：两种肺炎球菌结合疫苗，即15价（PCV15）和20价（PCV20）配方疫苗，按3 + 1程序被常规推荐用于美国儿童。前三剂在出生后第一年的2、4和6个月接种，而加强剂在12至15个月时接种。本研究评估了与PCV15相比，PCV20婴儿系列疫苗在出生后第一年的健康和经济影响。（2）方法：使用决策分析模型，我们计算了为随后五个出生队列引入PCV15或PCV20的健康和经济影响。流行病学数据来自同行评审研究，疫苗有效性估计值从已确定的PCV13有效性和PCV7效力研究中推断得出。与疾病治疗相关的直接医疗费用从文献中提取并按2024年美元进行通胀调整。（3）结果：在五年期间，预计在美国为新生儿接种PCV20疫苗，与PCV15相比，在随后五个出生队列的出生后第一年可额外预防220例侵袭性肺炎球菌疾病、6542例社区获得性肺炎和112,095例中耳炎。该策略可预防与这些疾病相关的66例婴儿死亡，并带来额外的健康收益，相当于5058个生命年和5037个质量调整生命年。据估计，这些预防的病例在5年内可节省约1.47亿美元。（4）结论：本研究表明，在美国，与PCV15相比，在出生后12个月内接种PCV20疫苗将产生显著更大的健康和经济回报，因为PCV20涵盖了另外五种血清型。
